Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jun;16(2):165-175.
doi: 10.1177/1534735416668575. Epub 2016 Sep 14.

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

Affiliations
Observational Study

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

Carolin C Hack et al. Integr Cancer Ther. 2017 Jun.

Abstract

Background: Breast cancer patients often use complementary and alternative medicine, but few prospectively collected data on the topic are available specifically for postmenopausal breast cancer patients. A large prospective study was therefore conducted within a noninterventional study in order to identify the characteristics of patients interested in integrative medicine.

Methods: The EvAluate-TM study is a prospective, multicenter noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive primary breast cancer. Between 2008 and 2009, 5045 postmenopausal patients were enrolled at 339 certified breast centers in Germany. As part of the data collection process, patients were asked at the baseline about their interest in and information needs relating to integrative medicine.

Results: Of the 5045 patients recruited, 3411 responded to the questionnaire on integrative medicine and took part in the analysis, 1583 patients expressed an interest in integrative medicine, and 1828 patients declared no interest. Relevant predictors of interest in integrative medicine were age, body mass index, tumor size, previous chemotherapy, and use of concomitant medications for other medical conditions. Interest in integrative medicine declined highly significantly ( P < .001) with age (<50 years, 74.1%; 50-60 years, 54.1%; >65 years, 38.0%). Patients in favor of integrative medicine were significantly less satisfied with the information received about individual treatments and antihormonal therapy. Patients with interest in integrative medicine were more often interested in rehabilitation and fitness, nutritional counseling, and additional support from self-help organizations. These women were mostly interested in receiving information about their disease and integrative medicine from a physician, rather than from other sources.

Conclusions: This study shows that a considerable proportion of postmenopausal breast cancer patients are interested in integrative medicine. Information about integrative medicine should therefore be provided as part of patient care for this group. It was found that receiving concomitant medication for other medical conditions is one of the main predictors for women not being interested in integrative medicine. This group of patients may need special attention and individualized information about integrative medicine. Additionally, most patients were interested in obtaining the relevant information from their doctor.

Keywords: aromatase inhibitor; breast cancer; complementary and alternative medicine; information; integrative medicine; letrozole; oncology; therapy management.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: PAF carried out research for Novartis and Amgen. KS and AJ are employees of Novartis Pharma. EB carried out research for Novartis, Celgene, BMS, and Roche. MWB is member of the EvAluate-TM study group. All other authors declare that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
Patient recruitment algorithm.

References

    1. Kaatsch P, Spix C, Hentschel S, et al. Krebs in Deutschland 2009/2010. Berlin, Germany: Robert Koch-Institut/die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.; 2013.
    1. Eisemann N, Waldmann A, Katalinic A. Epidemiology of breast cancer—current figures and trends. Geburtshilfe Frauenheilkd. 2013;73:130-135. - PMC - PubMed
    1. Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am. 2013;93:493-499. - PubMed
    1. Schmidt M. Chemotherapy in early breast cancer: when, how and which one? Breast Care (Basel). 2014;9:154-160. - PMC - PubMed
    1. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update. J Clin Oncol. 2014;32:2255-2269. - PMC - PubMed

Publication types